Expert Q&A – Page 2 – media

【EXPERT Q&A】How to optimize the process of pharmaceutical trade?

Drugdu.com expert’s response: Optimizing the pharmaceutical trade process is a crucial measure to enhance the efficiency of the pharmaceutical supply chain, reduce costs, and ensure the quality and safety of pharmaceutical products. Below are some specific optimization strategies: I. Digital and Information Technology Upgrading Implement ERP Systems: Functions: Integrate modules such as procurement, inventory, sales, and finance to achieve real-time data sharing and process automation. Advantages: Improve data processing efficiency, reduce human errors, and enhance decision-making support capabilities. Apply Blockchain Technology: Functions: Ensure the traceability of pharmaceutical products from production to sale, recording information at every stage. Advantages: Enhance pharmaceutical safety, boost consumer trust, and facilitate regulatory oversight. Utilize Big Data Analytics: Functions: Analyze data on market demand, sales trends, inventory levels, etc. Advantages: Optimize procurement plans, reduce inventory backlogs, and improve capital turnover rates. II. Supply Chain Collaboration and Integration Establish Strategic Partnerships: Methods: Form long-term and stable cooperative ...
- Source: drugdu
- 108
- June 27, 2025
【EXPERT Q&A】How exactly does the improvement of medical detection technology help discover more potential diseases?

Drugdu.com expert’s response: The advancement of medical detection technologies enables the discovery of more potential diseases through various means, which are specifically reflected in the following aspects: High-Sensitivity Detection Technologies: High-sensitivity detection methods can detect minute changes in biomarkers at an earlier stage. For instance, high-sensitivity troponin detection technology can identify the release of troponin during the early phase of myocardial cell injury, thereby supporting the early diagnosis of acute coronary syndrome and myocardial infarction. This technology can uncover early lesions that might be missed by traditional methods. Multimodal Data Fusion and Comprehensive Analysis: By integrating data from multiple detection modalities, such as electrocardiograms (ECGs), echocardiograms, and blood tests, medical detection technologies can provide more comprehensive health information. This multimodal data fusion enhances diagnostic accuracy and helps identify potential disease risks that might be overlooked by a single detection method. Artificial Intelligence (AI) and Big Data Analytics: AI technologies can ...
- Source: drugdu
- 118
- June 25, 2025
【EXPERT Q&A】What are the characteristics of the medical device industry?

Drugdu.com expert’s response: The medical device industry is characterized by its interdisciplinary nature, knowledge-intensive and capital-intensive requirements, stringent regulation, substantial market potential, low industry concentration, and fierce competition. The details are as follows: Interdisciplinary Nature: It encompasses disciplines such as engineering, medicine, physics, biology, materials science, computer science, human-computer interaction, and aesthetics, resulting in a high R&D threshold. Knowledge-Intensive and Capital-Intensive: It is a typical technology-intensive industry, with its development highly reliant on continuous technological R&D and innovation, necessitating significant capital investment. For instance, the initial funding for a medium-sized medical device project can reach as high as 30 million yuan. Stringent Regulation: It is subject to strict laws and regulations. The R&D, production, distribution, and use of medical device products must comply with relevant national standards, industry standards, and regulatory requirements, with complete and traceable records required throughout the product lifecycle. Substantial Market Potential: Driven by factors such as ...
- Source: drugdu
- 119
- June 23, 2025
【EXPERT Q&A】Is CDMO service for medical devices reliable?

Drugdu.com expert’s response: Medical device Contract Development and Manufacturing Organization (CDMO) services are reliable when they operate with strong compliance, technical expertise, and resource integration capabilities. However, potential risks such as intellectual property (IP) protection, industry trust, and policy changes should be noted. Below is a detailed analysis: Advantages of Medical Device CDMO Services High Specialization: Medical device CDMO companies typically possess extensive professional knowledge and practical experience, enabling them to provide one-stop services for medical device enterprises, ranging from product R&D and manufacturing to technical solutions. Cost Reduction: By outsourcing R&D and production processes, medical device enterprises can reduce investments in equipment, personnel, and facilities, thereby lowering R&D costs. Meanwhile, CDMO companies can leverage their advantages in large-scale production to reduce manufacturing costs and offer more competitive pricing to clients. Accelerated Market Launch: CDMO companies have professional R&D teams and rich practical experience, enabling them to provide efficient R&D ...
- Source: drugdu
- 129
- June 20, 2025
【EXPERT Q&A】How to register a drug with the DMF in the United States?

Drugdu.com expert’s response: The registration of a Drug Master File (DMF) for pharmaceuticals in the United States is a complex process involving multiple steps and requirements. Below are the main procedures and key points for registration: I. Determine the DMF Type Select the appropriate DMF type based on the product characteristics. Common types include: Type II: Manufacturing and control information for Active Pharmaceutical Ingredients (APIs) and intermediates, which is the most common type. Type III: Packaging materials. Type IV: Excipients. Type V: Information specifically requested by the FDA. II. Prepare Required Documents Cover Letter: Introduce the content and purpose of the DMF, including the DMF type. DMF Holder Information: Company name, address, contact person, etc. Letter of Authorization (LOA): If another company will reference this DMF, provide an LOA. Manufacturing Process Description: Detailed description of the production process and key process parameters. Quality Standards: Include specifications, impurities, and physicochemical properties, ...
- Source: drugdu
- 71
- June 18, 2025
【EXPERT Q&A】What are the mandatory certifications for product exports to the Middle East?

Drugdu.com expert’s response: I. Saudi Arabia SASO Certification: This certification involves pre-shipment inspection and conformity verification for products imported into the Saudi market, ensuring that imported goods comply with Saudi quality standards. SABER Certification: A system introduced by Saudi Arabia for online application of customs clearance certificates. It is used for product registration, issuance, and obtaining Certificates of Conformity (COC). SABER certification includes a Product Certificate (PC) and a Shipment Certificate (SC). All goods exported to Saudi Arabia must apply for an SC through the SABER system before the goods arrive at the port. II. Gulf Cooperation Council (GCC) Countries GCC Certification (G-MARK Certification): Applicable to the six Gulf countries, including Saudi Arabia, the United Arab Emirates, and Kuwait. It requires products to comply with the unified Gulf Standards (GSO). Products such as low-voltage equipment, toys, and building materials are involved, and they need to pass tests conducted by GSO-authorized ...
- Source: drugdu
- 105
- June 16, 2025
【EXPERT Q&A】What is the effect of rukang saltuzumab on EGFR-mutated lung cancer?

Drugdu.com expert’s response: I. Clinical Research Data KL264-01 Study: In the subgroup analysis targeting EGFR-mutated non-small cell lung cancer (NSCLC) patients, the objective response rate (ORR) of sacituzumab tirumotecan as a monotherapy reached as high as 55%, with a median progression-free survival (PFS) of 11.1 months. These results were significantly superior to those in EGFR wild-type patients, who had an ORR of 24% and a median PFS of 5.3 months. SKB264-II-08 Study: Among 64 previously treated EGFR-mutated NSCLC patients, sacituzumab tirumotecan achieved an ORR of 34%, a disease control rate (DCR) of 84%, a median duration of response (DOR) of 9.6 months, a median PFS of 9.3 months, and a 1-year overall survival (OS) rate of 79%. OptiTROP-Lung03 Study: The sacituzumab tirumotecan group demonstrated a confirmed ORR of 45.1%, significantly higher than the 15.6% in the docetaxel group. The median PFS was 6.9 months, significantly longer than the 2.8 months ...
- Source: drugdu
- 109
- June 13, 2025
【EXPERT Q&A】Is midazolam effective?

Drugdu.com expert’s response: Midazolam demonstrates significant efficacy in medical settings, yet its indications, dosage, and duration of use must be strictly controlled. Its effectiveness evaluation requires comprehensive consideration based on specific applications and individual differences. Below is an analysis of its efficacy across different usage scenarios: I. Notable Effects in Anesthesia and Sedation Anesthesia Induction and Maintenance: As a short-acting benzodiazepine, midazolam has a rapid onset (2-3 minutes after intravenous injection) and a short half-life (approximately 2 hours). It effectively reduces preoperative anxiety and aids in the induction of general anesthesia. When used in combination with anesthetics like propofol, it enhances the depth of sedation, maintains hemodynamic stability, and reduces the dosage requirements of other drugs. Sedation in Intensive Care: For mechanically ventilated patients, midazolam can quickly control agitation and reduce oxygen consumption, though the risk of respiratory depression must be vigilantly monitored. Its reversibility allows for relatively rapid patient ...
- Source: drugdu
- 90
- June 11, 2025
【EXPERT Q&A】What is the difference between siRNA and shRNA? How should the grouping for regular interference detection be set?

Drugdu.com expert’s response: I. Differences Between siRNA and shRNA 1. Structure and Composition siRNA (Small Interfering RNA): siRNA is a double-stranded RNA molecule, typically 20-25 base pairs in length, with a 2-nucleotide 3′ overhang at both ends. It consists of two complementary RNA strands: a sense strand (homologous to the target mRNA) and an antisense strand (complementary to the target mRNA). siRNA is usually generated from exogenous or endogenous double-stranded RNA through cleavage by the Dicer enzyme. shRNA (Short Hairpin RNA): shRNA is a single-stranded RNA capable of forming a hairpin (stem-loop) structure, comprising a short double-stranded region (19-29 bp) and a loop region. It consists of a sense strand, a loop sequence, and an antisense strand, forming a hairpin shape. shRNA is constructed into expression vectors through genetic engineering techniques and forms a hairpin structure upon transcription. 2. Mechanism of Action siRNA: After being cleaved by the Dicer enzyme, siRNA directly binds ...
- Source: drugdu
- 109
- June 9, 2025
【EXPERT Q&A】How to apply for medical device qualifications?

Drugdu.com expert’s response: The process of obtaining medical device qualifications involves multiple stages and stringent requirements, necessitating the preparation of corresponding materials and adherence to legal procedures based on the classification of medical devices (Class I, Class II, Class III) and the specific type of business operation (manufacturing or distribution). Below is a detailed explanation: I. Clarifying the Type of Qualification to Be Obtained Medical device qualifications are primarily categorized into manufacturing qualifications and distribution qualifications. These are further classified into Class I, Class II, and Class III based on the risk level of the medical devices. The requirements and procedures for obtaining qualifications vary across different categories. Class I Medical Devices: These pose a low risk and are subject to routine management. Generally, they only require filing and do not necessitate a license. Class II Medical Devices: These carry a moderate risk and require strict control and management. Distribution ...
- Source: drugdu
- 109
- June 6, 2025

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.